| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9ff8baa1da176a277fe6c1342beba43 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-6018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10331 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-193
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6897
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 |
| filingDate |
2015-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29384eea5eca08de482edaa82a93bf89 |
| publicationDate |
2016-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016106178-A1 |
| titleOfInvention |
Multitargeting onocolytic adenovirus, methods of use, and methods of making |
| abstract |
To increase the therapeutic potential of these oncolytic viruses based on a 24 base pair deletion in the viral E1 A gene (D24), a conditionally replicating adenovirus targeting multiple receptors upregulated on tumors was generated by incorporating an Ad5/3 fiber with a carboxyl terminus RGD ligand. The virus displayed full cytopathic effect in tumor lines assayed at low titers with improved cytotoxicity over Ad5-RGD D24, Ad5/3 D24 and an HSV oncolytic virus. The virus was further engineered to deliver immunotherapeutic agents such as GMCSF while maintaining enhanced heterogenic oncolysis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11723932-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019014391-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11471494-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111246865-A |
| priorityDate |
2014-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |